Pharmaflor SRL
2.8 FTEThe score of Pharmaflor shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Total assets +32 % Headcount (avg FTE) -24 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Pharmaflor's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 129,524 € | ||||
| Equity | 293,388 € | ||||
| Cash | 409,290 € | ||||
| EBITDA | 197,385 € | ||||
| Total assets | 831,466 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 18 Aug 2026
- Year ended 31 Dec 2024filed on 18 Aug 2025
- Year ended 31 Dec 2023filed on 06 Aug 2024
- Year ended 31 Dec 2022filed on 20 Jun 2023
- Year ended 31 Dec 2021filed on 29 Jul 2022
Pharmaflor's financial analysis
- Solvency35.3%sector median: 41.5%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Pharmaflor
Pharmaflor's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0882.105.726
- VAT number
- BE0882105726
- Peppol
- Registered · 0208:0882105726 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 26 Jun 2006
- Registered office
- 5020 Namur
- Size
- Micro · 2.8 FTE
- Latest accounts
- 2025 · filed on 18 Aug 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Pharmaflor (SRL) has been based in Namur since 2006, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 129,524 € and equity of 293,388 €; its revenue is not published. With 2.8 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 35.3%, below the median of its sector (41.5%).
Companies similar to Pharmaflor
Companies in the same business, of comparable size and area, outside its group.
- apotheek Maes Retail sale of pharmaceutical products Hoegaarden · balance sheet 831,494 €
- Haelvoetpharma Retail sale of pharmaceutical products Evere · balance sheet 906,520 €
- Pharmacie Rosart-Humblet Retail sale of pharmaceutical products Floreffe · balance sheet 946,558 €
- Boeyckens Retail sale of pharmaceutical products Vilvoorde · balance sheet 713,576 €
- Proxypharma LLB Retail sale of pharmaceutical products La Bruyère · balance sheet 707,554 €
- License to care Retail sale of pharmaceutical products Duffel · balance sheet 702,743 €
- BIO - Vitalpharma Retail sale of pharmaceutical products Antwerp · balance sheet 532,020 €
- LAB 06 Retail sale of pharmaceutical products Écaussinnes · balance sheet €1.31m
Frequently asked questions about Pharmaflor
What is the revenue of Pharmaflor?
Pharmaflor files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Pharmaflor?
In Belgium, the VAT number is the company number prefixed with BE: BE0882105726 for Pharmaflor, if the company is VAT-registered. Its company number (CBE) is 0882.105.726.
Where is the registered office of Pharmaflor?
According to the CBE register, the registered office of Pharmaflor is in 5020 Namur.
What is the equity of Pharmaflor?
At the close of the 2025 financial year, the equity of Pharmaflor amounts to 293,388 €, a solvency of 35.3% of total assets.
How many people work at Pharmaflor?
2.8 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Pharmaflor?
The register lists 1 active mandates at Pharmaflor. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Pharmaflor
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →